1. Academic Validation
  2. Myocardial ischemia/reperfusion injury: potential of TRPV1 agonists as cardioprotective agents

Myocardial ischemia/reperfusion injury: potential of TRPV1 agonists as cardioprotective agents

  • Cardiovasc Hematol Disord Drug Targets. 2014;14(1):71-8. doi: 10.2174/1871529x13666131129103759.
Praveen Vemula Bikki Gautam George S Abela Donna H Wang 1
Affiliations

Affiliation

  • 1 Division of Nanomedicine and Molecular Intervention, Department of Medicine, B316 Clinical Center, Michigan State University, East Lansing, MI 48824, USA. vemulapr@msu.edu.
Abstract

Myocardial Ischemia/Reperfusion (I/R) induced injury has widespread detrimental effects partially negating the benefits obtained from early revascularization in Acute Myocardial Infarction. Various complex mechanisms contribute to I/R injury and different agents targeting those specific mechanisms are being studied. Despite continued research and widespread interest, none of them have become incorporated into everyday practice. The TRPV1 (transient receptor potential vanilloid 1) channel is a non selective cation channel predominantly expressed in sensory neurons with the nerve fibers innervating the heart and blood vessels. Multiple studies have demonstrated the importance of the activation of TRPV1 and subsequent release of sensory neurotransmitters in cardioprotection. This review focuses on the role of TRPV1 in prevention of cardiac I/R injury, the work that has been done so far and future implications for TRPV1 agonists as cardioprotective agents.

Figures
Products